Incyte Corporation
INCY
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor tā¦ read more
Healthcare
Biotechnology
32 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$105.98
Price+0.74%
$0.78
1Y
Price
Market Cap
$20.806b
Large
Price/Earnings 3y Avg5y Avg
18x
Premium
Premium
Financials Overview
Key metrics over the past few years+33.3%
EBITDA Margin+31.1%
Net Profit Margin+39.9%
Free Cash Flow MarginRevenue
$4.813b
+13.5%
1y CAGR+12.4%
3y CAGR+12.7%
5y CAGREarnings
$1.189b
+3544.3%
1y CAGR+1175.1%
3y CAGR+865.3%
5y CAGREPS
$5.97
+3880.0%
1y CAGR+1286.7%
3y CAGR+948.9%
5y CAGRBook Value
$4.651b
$6.330b
Assets$1.679b
Liabilities$35.372m
DebtDebt to Assets
0.6%
-
Debt to EBITDAFree Cash Flow
$1.197b
+380.6%
1y CAGR+95.5%
3y CAGR+85.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company